Literature DB >> 29057203

Nanotechnological Approaches to Immunosuppression and Tolerance Induction.

Kunal Patel1,2, Carl Atkinson1,2,3, Danh Tran1,2, Satish N Nadig1,2,3.   

Abstract

PURPOSE OF REVIEW: Several preclinical studies have engineered nanoparticles for immune regulation, and have shown promising results in the fields of autoimmunity and cancer. In solid organ transplantation, the use of nanoparticle-based immune regulation has only just begun to emerge but holds significant promise for the improvement of our current standard of care immunosuppressive regimens. In this review, we will shed light on the current status of nanoparticle-engineered immunotherapeutics, and the potential application of these technologies to the field of organ transplantation. Further we discuss different strategies for delivery and potential cellular targeting moieties that could be utilized to obviate the need for high dose systemic immunosuppressive regimens. RECENT
FINDINGS: Recent studies have shown the potential of immunosuppressive laden nanoparticles to increase bioavailability, drug release, and specifically target immune cell compartments as methods to provide recipient immunosuppressive sparing strategies.
SUMMARY: Nanoparticle centered immunosuppressive strategies hold the potential to usher in a new era in transplant recipient management and could hold the key to minimizing off-target effects of immunosuppressants, along with prolonging transplant survival.

Entities:  

Keywords:  Immunity; Immunosuppression; Nanoparticle; Targeting; Transplant Rejection

Year:  2017        PMID: 29057203      PMCID: PMC5647816          DOI: 10.1007/s40472-017-0146-9

Source DB:  PubMed          Journal:  Curr Transplant Rep


  76 in total

Review 1.  Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.

Authors:  Jagdish L Italia; Vivekanand Bhardwaj; M N V Ravi Kumar
Journal:  Drug Discov Today       Date:  2006-09       Impact factor: 7.851

Review 2.  Novel preservation methods to increase the quality of older kidneys.

Authors:  Aukje Brat; Robert A Pol; Henri G D Leuvenink
Journal:  Curr Opin Organ Transplant       Date:  2015-08       Impact factor: 2.640

3.  A randomized trial of inhaled cyclosporine in lung-transplant recipients.

Authors:  Aldo T Iacono; Bruce A Johnson; Wayne F Grgurich; J Georges Youssef; Timothy E Corcoran; Deidre A Seiler; James H Dauber; Gerald C Smaldone; Adriana Zeevi; Samuel A Yousem; John J Fung; Gilbert J Burckart; Kenneth R McCurry; Bartley P Griffith
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

4.  Safety and toxicology of cyclosporine in propylene glycol after 9-month aerosol exposure to beagle dogs.

Authors:  Ralph Niven; Maryellen Lynch; Ronald Moutvic; Seth Gibbs; Crystal Briscoe; Howard Raff
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-04-08       Impact factor: 2.849

5.  Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion.

Authors:  Elaine K Horibe; Justin Sacks; Jignesh Unadkat; Giorgio Raimondi; Zhiliang Wang; Ryosuke Ikeguchi; Douglas Marsteller; Lydia M Ferreira; Angus W Thomson; W P Andrew Lee; Maryam Feili-Hariri
Journal:  Transpl Immunol       Date:  2007-11-05       Impact factor: 1.708

6.  Preclinical safety evaluation of inhaled cyclosporine in propylene glycol.

Authors:  Tao Wang; Sarah Noonberg; Ronald Steigerwalt; Maryellen Lynch; Rosemary A Kovelesky; Carlos A Rodríguez; Katherine Sprugel; Nancy Turner
Journal:  J Aerosol Med       Date:  2007

7.  Nanoencapsulation of tacrolimus in lipid-core nanocapsules showed similar immunosuppressive activity after oral and intraperitoneal administrations.

Authors:  R B Friedrich; F A Dimer; S S Guterres; R C R Beck; A R Pohlmann
Journal:  J Biomed Nanotechnol       Date:  2014-08       Impact factor: 4.099

8.  Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients.

Authors:  T E Corcoran; R Niven; W Verret; S Dilly; B A Johnson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-05-13       Impact factor: 2.849

Review 9.  Extended release once a day tacrolimus.

Authors:  Neeraj Singh; Jon Von Visger; Mareena Zachariah
Journal:  Curr Opin Organ Transplant       Date:  2015-12       Impact factor: 2.640

10.  Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2.

Authors:  Chen Wang; Lingfeng Qin; Thomas D Manes; Nancy C Kirkiles-Smith; George Tellides; Jordan S Pober
Journal:  J Exp Med       Date:  2014-02-10       Impact factor: 14.307

View more
  5 in total

1.  Nanodelivery of Mycophenolate Mofetil to the Organ Improves Transplant Vasculopathy.

Authors:  Mayuko Uehara; Baharak Bahmani; Liwei Jiang; Sungwook Jung; Naima Banouni; Vivek Kasinath; Zhabiz Solhjou; Jing Zhao; Farideh Ordikhani; Munhyung Bae; Nasim Annabi; Martina M McGrath; Reza Abdi
Journal:  ACS Nano       Date:  2019-09-25       Impact factor: 15.881

2.  Intra-Organ Delivery of Nanotherapeutics for Organ Transplantation.

Authors:  Bilal Hussain; Vivek Kasinath; Joren C Madsen; Jonathan Bromberg; Stefan G Tullius; Reza Abdi
Journal:  ACS Nano       Date:  2021-10-29       Impact factor: 18.027

Review 3.  Macrophages in Organ Transplantation.

Authors:  Farideh Ordikhani; Venu Pothula; Rodrigo Sanchez-Tarjuelo; Stefan Jordan; Jordi Ochando
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

Review 4.  PLGA-Based Composites for Various Biomedical Applications.

Authors:  Cátia Vieira Rocha; Victor Gonçalves; Milene Costa da Silva; Manuel Bañobre-López; Juan Gallo
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

Review 5.  Implantable Immunosuppressant Delivery to Prevent Rejection in Transplantation.

Authors:  Madonna Rica Anggelia; Ren-Wen Huang; Hui-Yun Cheng; Chih-Hung Lin; Cheng-Hung Lin
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.